scholarly journals Chronic urticaria and inflammatory bowel disease — is it worth looking further?

2021 ◽  
pp. 55-60
Author(s):  
O.M. Okhotnikova ◽  
◽  
A.A. Romanchuk ◽  
O.M. Grishchenko ◽  
◽  
...  

Chronic urticaria is a common disease that also occurs against the background of inflammatory bowel disease. This case draws attention to the common pathophysiology between autoimmune and autoinflammatory diseases and the need for careful differential diagnosis and further research, which can significantly influence the choice of treatment tactics. Clinical case. An 9-year-old girl with chronic urticaria from birth and recurrent episodes of fever and conjunctivitis was examined at the pediatric ward of the National Children's Specialized Hospital «OKHMATDYT». On the basis of negative results of determination of serum level of immunoglobulins A to gliadin and endomysia celiac disease is excluded, and also by means of modern methods of allergodiagnostics (skin prick-tests, cold test, molecular allergodiagnostics, elimination dietodiagnostics) influence of various is excluded. The girl was diagnosed with chronic idiopathic urticaria with inflammatory bowel disease with trial treatment with ketatifen, bilastine and mesalazine. Due to complaints of recurrent rashes and fever on the background of this therapy, the anamnesis of the disease was re-analyzed and the material was sent for genetic sequencing, which allowed to change the diagnosis to auto-inflammatory disease and prescribed therapy — daily administration of anakinra. Since then, she no longer has recurrent febrile fever or urticaria, and the level of markers of inflammation has returned to normal. Conclusions. This clinical example is interesting for a complex diagnostic search, when a combination of chronic urticaria and inflammatory bowel disease was observed without effect on therapy, which forced to reconsider the diagnosis, which turned out to be even rarer and was finally confirmed by genome sequencing. But despite the fact that the diagnosis was different, it is interesting that on the background of taking mesalazine the girl's condition still improved slightly: became less likely to bother urticarial rash and fever on the background of the rash, which may indicate some common pathogenetic features of inflammation in intestines and chronic idiopathic urticaria, which has an indisputable scientific and practical interest. The research was carried out in accordance with the principles of the Helsinki declaration. The informed consent of the patient was obtained for conducting the studies. No conflict of interest was declared by the authors. Key words: urticaria, inflammatory bowel disease, autoinflammatory diseases, interleukinE1, Biologics, anakinra.

2021 ◽  
Vol 27 (Supplement_1) ◽  
pp. S53-S53
Author(s):  
Joshua Paulton ◽  
Amanjot Gill ◽  
Joelle Prevost

Abstract Background Gut-directed hypnosis (GDH) is a complimentary therapy for Inflammatory Bowel Disease (IBD), that can be learnt by patients to practice self-hypnosis. GDH in IBD has augmented remission and improved inflammation. GDH has a history of successful use for Irritable Bowel Syndrome (IBS). In IBD it may also improve IBS-like symptoms in remission and recovery from surgery. GDH is suitable for youth and adult IBD patients. In hypnosis, a relaxed state is inducted then suggestions to subconscious mind processes are made. In IBD, the mechanism of action of GDH is unknown but may influence the disease stress response. Aims Aims are the development of a GDH self-hypnosis protocol for IBD, with appropriate target symptoms. Patients first learn to practice with a clinician, then as complimentary psychotherapy for remission augmentation, IBS-like symptoms, and surgery recovery. Methods GDH is practiced first with a clinician, and then by patients as self-hypnosis (table 1). Patients receive psycho-education on GDH for IBD. Next, appropriate treatment goals are made, based on target symptoms. Relaxation techniques induce patient to a deeply relaxed state. Therapeutic suggestions specific to patient goals are given: verbal suggestions, visualizations, and post-hypnotic suggestions. Suggestions can focus on having a healthy digestive system, inflammation and symptoms reduction, and achievement and sustainment of remission. Patients emerge from hypnosis, are debriefed, and encouraged to practice ongoing self-hypnosis. Results In IBD, GDH self-hypnosis can be learnt from clinicians and practiced by patients as a complimentary therapy. Patients’ achievement and sustainment of remission, with clinical markers of inflammation can be monitored. Patients can monitor subjective improvement of IBS-like symptoms and post surgery, recovery progress can be monitored. Conclusions GDH has a history of use for IBS. In IBD, it has been shown to modulate remission, and may improve IBS-like symptoms, and in surgery recovery. The mechanism of action of GDH in IBD may influence the disease stress response. Clinicians trained in GDH are limited currently. Patients may learn GDH self- hypnosis to as a complimentary psychotherapy.


Molecules ◽  
2021 ◽  
Vol 26 (7) ◽  
pp. 1843
Author(s):  
Marilyn Hagan ◽  
Bu' Hussain Hayee ◽  
Ana Rodriguez-Mateos

(Poly)phenols (PPs) may have a therapeutic benefit in gastrointestinal (GI) disorders, such as irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD). The aim of this review is to summarise the evidence-base in this regard. Observational evidence does not give a clear indication that PP intake has a preventative role for IBD or IBS, while interventional studies suggest these compounds may confer symptomatic and health-related quality of life improvements in known patients. There are inconsistent results for effects on markers of inflammation, but there are promising reports of endoscopic improvement. Work on the effects of PPs on intestinal permeability and oxidative stress is limited and therefore conclusions cannot be formed. Future work on the use of PPs in IBD and IBS will strengthen the understanding of clinical and mechanistic effects.


Immunology ◽  
2013 ◽  
Vol 140 (1) ◽  
pp. 87-97 ◽  
Author(s):  
Nicholas T. Funderburg ◽  
Samantha R. Stubblefield Park ◽  
Hannah C. Sung ◽  
Gareth Hardy ◽  
Brian Clagett ◽  
...  

1995 ◽  
Vol 9 (7) ◽  
pp. 397-400
Author(s):  
E Jan Irvine

Several activity indices have been developed to assess the efficacy of new therapies for inflammatory bowel disease. The ideal index should be simple to administer and quantitative. It should be a composite of subjective symptoms, objective findings and laboratory markers of inflammation. Any newly developed indices should be assessed for validity, reliability and responsiveness before application in clinical trials. Obstacles to standardizing disease activity relate to the heterogeneity of disease manifestations, the characteristics of the study population, the therapy being tested, the investigators' preference for which index to apply and the attributes of the index. Examples of available indices are identified, some of their limitations are discussed, and guidelines for how to select an index for a clinical trial are outlined.


2021 ◽  
Vol 4 (Supplement_1) ◽  
pp. 192-194
Author(s):  
J P Paulton ◽  
J Prevost ◽  
A K Gill

Abstract Background Gut-directed hypnosis (GDH) is a complimentary therapy for Inflammatory Bowel Disease (IBD), that can be learnt by patients to practice self-hypnosis. GDH in IBD has augmented remission and improved inflammation. GDH has a history of successful use for Irritable Bowel Syndrome (IBS). In IBD it may also improve IBS-like symptoms in remission and recovery from surgery. GDH is suitable for youth and adult IBD patients. In hypnosis, a relaxed state is inducted then suggestions to subconscious mind processes are made. In IBD, the mechanism of action of GDH is unknown but may influence the disease stress response. Aims Aims are the development of a GDH self-hypnosis protocol for IBD, with appropriate target symptoms. Patients first learn to practice with a clinician, then as complimentary psychotherapy for remission augmentation, IBS-like symptoms, and surgery recovery. Methods GDH is practiced first with a clinician, and then by patients as self-hypnosis (table 1). Patients receive psycho-education on GDH for IBD. Next, appropriate treatment goals are made, based on target symptoms. Relaxation techniques induce patient to a deeply relaxed state. Therapeutic suggestions specific to patient goals are given: verbal suggestions, visualizations, and post-hypnotic suggestions. Suggestions can focus on having a healthy digestive system, inflammation and symptoms reduction, and achievement and sustainment of remission. Patients emerge from hypnosis, are debriefed, and encouraged to practice ongoing self-hypnosis. Results In IBD, GDH self-hypnosis can be learnt from clinicians and practiced by patients as a complimentary therapy. Patients’ achievement and sustainment of remission, with clinical markers of inflammation can be monitored. Patients can monitor subjective improvement of IBS-like symptoms and post surgery, recovery progress can be monitored. Conclusions GDH has a history of use for IBS. In IBD, it has been shown to modulate remission, and may improve IBS-like symptoms, and in surgery recovery. The mechanism of action of GDH in IBD may influence the disease stress response. Clinicians trained in GDH are limited currently. Patients may learn GDH self-hypnosis as a complimentary psychotherapy. Funding Agencies None


2014 ◽  
Vol 59 (4) ◽  
pp. 505-510 ◽  
Author(s):  
Yixi Huang ◽  
Daniel A. Lemberg ◽  
Andrew S. Day ◽  
Barbara Dixon ◽  
Steven Leach ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document